Altimmune: Don't Buy The GLP-1 Move-Up [Seeking Alpha]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Seeking Alpha
Altimmune's pipeline is young and faces strong competition in the GLP-1 market, as well as challenges in the NASH space. Shareholder dilution is another tangible risk that prospective investors will likely have to grapple with. Introduction Shares of Altimmune ( NASDAQ: ALT surged last Thursday during after-hours trading following the release of positive data from MOMENTUM, which is a phase two trial evaluating the effect of their GLP-1/glucagon dual receptor agonist (Pemvidutide) as a treatment for obesity. The top-line data were strongly positive. A dose-dependent and statistically significant weight loss reduction was shown. There were no major adverse events, and the discontinuation rate for placebo exceeded that of the treatment arms. At face value, this looks like a home-run. Yet still, the stock slid from ~$5.80 from the first initial market open to ~$4.50 as of the time of writing. Investors seem broadly optimistic, yet, there may be more than meets the eye with Pemvi
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain [Seeking Alpha]Seeking Alpha
- Viking Therapeutics (VKTX) Is Up 8.9% After Rival Data Bolsters Its Oral Obesity Program [Yahoo! Finance]Yahoo! Finance
- Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (VKTX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics (VKTX): Rethinking Valuation After a Sharp Pullback and Strong Multi-Year Run [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Sec Filings
- 11/5/25 - Form SCHEDULE
- 10/28/25 - Form 4
- 10/28/25 - Form 4
- VKTX's page on the SEC website